Navigation Links
Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions

PITTSBURGH, Nov. 18, 2010 /PRNewswire/ -- Neuro Kinetics, Inc. (NKI) (, manufacturers of noninvasive medical diagnostic equipment used worldwide to test for vestibular and neurological conditions, said today that it has received a two-part grant under the recently enacted Patient Protection and Affordable Care Act to further the company's ongoing clinical studies to collect data for the objective diagnosis of sports concussions.

The Therapeutic Discovery grant was awarded by the U.S. Department of Health and Human Services (HHS).

According to the U.S. Centers for Disease Control, an estimated three million sports-related concussions occur annually in the United States.  For young people ages 15 to 24, sports are second only to automobile accidents as the leading cause of Traumatic Brain Injuries (TBI) and mild Traumatic Brain Injuries (mTBI).

"With much attention focused recently on brain injuries in professional and high school football, there is widespread awareness of just how devastating brain injuries can be over time. Our I-Portal® eye-tracking technology is proving to provide repeatable and objective diagnosis of brain injuries inflicting all athletes in contact sports, from school through professional ranks," said Howison Schroeder, NKI president and CEO. "As with so many medical issues, accurate and timely diagnosis means better patient care, and that can be a life-changer for a brain injury victim."

NKI is working with a major hospital to expand a database of baseline brain functioning for student athletes in Western Pennsylvania.

"We have already been able to compare a dozen concussion incidents with the baseline data," Schroeder. "We are encouraged that our technology appears to offer an early indication of whether there is brain injury."

The HHS grant will be used to further that research, Schroeder said.

NKI's research into accurate diagnosis of sports concussions continues the company's strategy of expanding the clinical utility of its testing equipment and the range of tests that can be conducted with them.

The company also is engaged in extensive research with a number of U.S. military hospitals and healthcare facilities to develop new techniques for early diagnosis of TBI and mTBI suffered by soldiers from roadside blasts in Afghanistan and Iraq.  The investigations center on whether neuro-otologic measurements included in the battery of tests available through Neuro Kinetics' I-Portal® NOTC (Neuro-Otologic Test Center) and I-Portal® VNG (Video Nystagmography) systems can provide objective and repeatable neuro-physiologic evaluations for mTBI.  If so, accurate diagnosis of mTBI -- and therefore improved care -- would be possible.

NKI is the pioneer of the renowned computerized Barany (rotational) chair to test for vestibular and neurological issues. The company's equipment and related software generate precise motion, ocular motor, and optokinetic stimuli in conjunction with highly accurate measurement of the eye's horizontal, vertical, pupil and torsional responses or reflexive reactions to the stimuli.  The precision of the testing and accuracy of results helps clinicians develop more timely and accurate diagnosis.

"We believe that we on the verge of a new era in diagnostic testing and that the eye is the portal to the brain.  Abnormal responses of the eye can be the first indication of more than 200 diseases and conditions," said Schroeder. "With the quality of life for our soldiers and athletes at stake, our work in the development of objective and accurate diagnosis of brain injuries could benefit many, many people."


Neuro Kinetics, Inc. (NKI) is the world leader in eye tracking technology and non-invasive neuro-otologic diagnostic testing.Central to its product mix and technological advances is the premise that the eye is the portal to the brain.  Research has shown the detection of abnormal eye reflexes can indicate the presence of over 200 diseases and medical conditions. 

For more than 25 years, NKI has supplied comprehensive neuro-otologic diagnostic tools to audiologists, ENT's, neuro-otologists, neuro-ophthalmologists and neurologists around the globe.  The company's patented products include the I-Portal® NOTC (Neuro-Otologic Test Center), I-Portal® VNG (Video Nystagmography) and I-Portal® VOG (Video Oculography), along with related accessories, software, training and support services. MEDIA CONTACTJohn BuckmanBuckman Communications, for Neuro Kinetics, Inc.+ 1 412-381-2900 or

SOURCE Neuro Kinetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
2. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
3. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump™ and ResQPOD® CPR Devices
4. Neurologix Reports Third Quarter 2010 Financial Results
5. Reportlinker Adds Neuroprotection - Drugs, Markets and Companies
6. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
7. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
8. Neurocrine Biosciences Reports Third Quarter 2010 Results
9. Pfizers Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
10. Boston Scientific Agrees to Sell Neurovascular Business to Stryker
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
Post Your Comments:
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... Dec. 1, 2015   Craneware, Inc ., ... solutions, today announced the company will showcase a ... ® solution at the American Society ... Meeting . The new features are focused on ... monitoring and managing enterprise-wide pharmacy charges to ensure ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville ... is the only hospital in the region providing what is known as the ... pacing patients were revealed recently at a medical conference and published in The ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, “ ... a main “pain point” for merging or aligning healthcare provider organizations—when mergers and ... signed. This quick-read guidance suggests that failing to recognize the power of ...
Breaking Medicine News(10 mins):